Psychedelics


Dr. Jeffrey Kamlet Internationally Recognized Expert on Cardiac Safety in Ibogaine Treatment Joins Ehave as Chief Medical Officer

June 15th, 2021 - Ryan Allway

New Position Created to Deepen Clinical Expertise and Advance Pipeline Clinical Programs   MIAMI, June 15, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today the appointment of Jeffrey D. Kamlet, MD, FASAM, DABAM to the position of Chief […]

atai Life Sciences Announces Launch of Initial Public Offering

June 14th, 2021 - Ryan Allway

atai Life Sciences B.V. (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the commencement of a proposed underwritten initial public offering of 14,286,000 of its common shares. All common shares to be sold in the proposed offering will be sold by atai. The underwriters of the offering […]

NeonMind Announces Vitasave Will Carry NeonMind Functional Mushroom Products

June 10th, 2021 - Ryan Allway

Vancouver, B.C. – June 10, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind”), is pleased to announce that Vitasave has agreed to carry all four of NeonMind’s functional mushroom infused coffees through Vitasave’s eCommerce platform.   Vitasave is a Canadian owned and operated natural health company headquartered in British Columbia, with warehouses in […]

Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients

June 8th, 2021 - Ryan Allway

Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has entered into a Scientific Research Agreement (SRA) with the University of California San Francisco (UCSF). This SRA will leverage four other clinical […]

Pharmadrug’s Supersmart Launches Psilocybin Online Retail Platform in the Netherlands

June 7th, 2021 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – June 7, 2021) – PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“) a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that its Super Smart division has launched a […]

Ketamine One Signs Definitive Agreement to Acquire Integrated Rehab and Performance Ltd.

June 3rd, 2021 - Ryan Allway

VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (formerly, Myconic Capital Corp.) (“Ketamine One” or the “Company”) (NEO: MEDI), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has entered into a definitive agreement (the “Agreement”) based […]

Optimi Health Announces DTC Eligibility & Up-List to OTCQB

June 3rd, 2021 - Ryan Allway

VANCOUVER, BC (GLOBE NEWSWIRE – June 3, 2021) — Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that its US-based OTC Markets listing under the symbol “OPTHF” has received approval from the Depository […]

Optimi Health Announces DTC Eligibility & Up-List to OTCQB

June 3rd, 2021 - Ryan Allway

VANCOUVER, BC (GLOBE NEWSWIRE – June 3, 2021) — Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that its US-based OTC Markets listing under the symbol “OPTHF” has received approval from the Depository […]

Silo Wellness Partners with Mushe Inc. to Establish First Legal Brick & Mortar Psychedelic and Functional Mushroom Shop in the Western Hemisphere

June 2nd, 2021 - Ryan Allway

MONTEGO BAY, Jamaica, June 02, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness” or “the Company”) (CSE: SILO) (FRA: 3K70), a leading global psychedelics company, today announced it has signed a binding letter of intent with Canadian-based mushroom company Mushe Inc. (“Mushe”) to establish the first legal functional and psychedelic mushroom retail outlet in the […]

BetterLife Pharma Appoints Henri Sant-Cassia of The Conscious Fund to its Board of Directors

June 2nd, 2021 - Ryan Allway

VANCOUVER, British Columbia, June 02, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce that it has appointed Mr. Henri Sant-Cassia, co-founder of The Conscious Fund, to its Board of Directors.   Mr. Sant-Cassia has 10 […]

The Good Shroom Co Signs Contract With Top Tier Canadian Retail Distributor Ecotrend

June 1st, 2021 - Ryan Allway

MONTREAL, June 1, 2021 /CNW/ – The Good Shroom Co Inc. (the “Company” or “TGSC”) (TSXV: MUSH), a Quebec based company that manufactures and sells functional beverages under its two brands: Teonan® and Velada™, has entered into a distribution and sales agreement with Ecotrend Ecologics Ltd (“Ecotrend”)., a respected top tier natural health products distribution […]

Filament Health Partners with TrPR Psychedelic Research Program at UCSF to Advance First Drug Candidates Through FDA Phase 1 and Phase 2 Clinical Trials

June 1st, 2021 - Ryan Allway

Filament Health is collaborating with the TrPR Program at the University of California, San Francisco on two innovative U.S. FDA clinical trials, commencing in 2021, to demonstrate the safety and efficacy of its proprietary, naturally-extracted drug candidates.   Vancouver, British Columbia, May 31, 2021 – Filament Ventures Corp. (“Filament”, “Filament Health” or the “Company”), an exclusively-natural […]

Field Trip Health Ltd. Receives Conditional Approval to Up-List to the Toronto Stock Exchange

May 28th, 2021 - Ryan Allway

TORONTO, May 27, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (“Field Trip“), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has received conditional approval to list its common shares and warrants on the Toronto Stock Exchange (TSX). The listing is subject […]

Defiance ETFs Launches $PSY, the First U.S.-listed ETF Focused on Psychedelics

May 28th, 2021 - Ryan Allway

NEW YORK, May 28, 2021 /PRNewswire/ — Today, Defiance ETFs launched $PSY, the Defiance Next Gen Altered Experience ETF, the first psychedelic ETF to be listed in the U.S. $PSY will give investors exposure to companies involved in the development of the next generation of medicine, including psychedelics, cannabis and other psychedelic derived treatments.   About Defiance: Founded in 2018, Defiance is a […]

Psyence Group Corporate Update

May 27th, 2021 - Ryan Allway

TORONTO, May 27, 2021 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three clear paths to revenue and value creation namely: Psyence Production, Psyence Therapeutics and Psyence Function.   Psyence Production Psyence is federally licensed to cultivate and export psilocybin mushrooms […]

Leading Psychedelic Wellness Platform, Delic, Completes Acquisition of Complex Biotech Discovery Ventures Ltd.

May 27th, 2021 - Ryan Allway

  New Entity, Delic Labs, to Power Psilocybin and Cannabis R&D, IP and Innovative Product Lines for Mass Markets VANCOUVER, BC, May 27, 2021 /PRNewswire/ – Delic Holdings Inc. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness platform, is pleased to announce that it has acquired all of the issued and outstanding shares in the capital of Complex […]

MYND Life Sciences Inc. Announces Public Listing on the Canadian Securities Exchange

May 26th, 2021 - Ryan Allway

VANCOUVER, BC, May 26, 2021 /PRNewswire/ – MYND Life Sciences Inc. (“MYND“), a life sciences company focused on novel psychedelic drug development and pharmaceuticals, is pleased to announce its shares have been approved for listing on the Canadian Securities Exchange (“CSE“). The Company’s shares will commence trading at market open on May 26, 2021, under the symbol ‘MYND’.   […]

OPTIMI HEALTH APPOINTS CHIEF SCIENCE OFFICER

May 26th, 2021 - Ryan Allway

Company welcomes leadership oversight of new product research, formulations & trials   VANCOUVER, BC (GLOBE NEWSWIRE – May 26, 2021) — Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce the engagement of Mr. […]

NeonMind Announces Creation of Medical Clinics Advisory Board to Guide Planning and Operation of Company-Branded Clinics Across Canada

May 26th, 2021 - Ryan Allway

Vancouver, B.C. – May 26, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FFE: 6UF) (“NeonMind”), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, is pleased to announce the formation of a Medical Clinic Advisory Board to guide the planning and operation of […]

Cybin Files an International Patent Application Further Strengthening its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions

May 26th, 2021 - Ryan Allway

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed an international patent application that brings the potential to obtain patent coverage in 153 countries. The application, governed by the Patent Cooperation Treaty (“PCT”), grants the Company the right to file future national […]

Medxtractor Looks to Transform Mobile Health with Machine-Learning

May 26th, 2021 - Ryan Allway

Machine-Learning (“ML”) (sometimes referred to as artificial intelligence or “AI”) has experienced a renaissance over the past five years thanks to a combination of big data, fast processors, and new algorithms. ML is all around us; from stock trading to autonomous vehicles, ML is already transforming a wide range of industries by finding patterns in […]

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

May 25th, 2021 - Ryan Allway

DENVER, May 25, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced today that it has received approval from Health Canada to significantly expand its […]

Tryp Therapeutics Partners with Alcami for Proprietary Formulations

May 25th, 2021 - Ryan Allway

San Diego, California–(Newsfile Corp. – May 25, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) (“Tryp”), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with Alcami Corporation (“Alcami”), a global pharmaceutical contract development and manufacturing organization (CDMO), to support the […]

PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease

May 25th, 2021 - Ryan Allway

TORONTO, May 25, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has filed an application with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for ketamine to treat amyotrophic lateral sclerosis (“ALS”), […]

NASDAQ-listed Enveric Acquires MagicMed to Bring Psychedelics Derivatives to Market

May 25th, 2021 - Ryan Allway

 Enveric Biosciences (NASDAQ: ENVB), best-known for its pipeline of naturally occurring cannabinoid compounds, recently entered into a definitive agreement to acquire MagicMed Industries, a private biotechnology company focused on building a library of novel derivative psychedelic molecules with applications across multiple indications. The transaction broadens Enveric Bioscience’s focus into psychedelics and complements its existing pipeline […]

MindMed Announces Launch of Collaboration with Nextage Therapeutics’ Brain Targeting Liposome System

May 24th, 2021 - Ryan Allway

NEW YORK, May 24, 2021 /CNW/ — MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company, announce the execution of a Memorandum of Understanding (the “MOU”) regarding the launch of an exclusive collaborative development program to optimize the delivery […]

Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives

May 24th, 2021 - Ryan Allway

With this acquisition, Enveric will expand and complement its pipeline of naturally occurring cannabinoid compounds with a robust portfolio of psychedelic-derived molecules Enveric aims to move into the clinic with novel cannabinoid and psychedelic-derived therapies to improve standard of care and serve unmet needs across multiple indications including oncology and CNS, such as PTSD Upon […]

Filament Announces C$10M Offering and Filing of Initial Listing Application

May 21st, 2021 - Ryan Allway

VANCOUVER, BC, May 17, 2021 /CNW/ – Filament Ventures Corp. (“Filament” or the “Company”), an exclusively-natural psychedelic drug discovery and extraction company, is pleased to announce that it has entered into an agreement with Echelon Wealth Partners Inc. and Canaccord Genuity Corp. (together, the “Co-Lead Agents”) to sell, by way of a private placement on […]

Wake Network Successfully Completes First Legal Psilocybin Mushroom Import into The United States

May 20th, 2021 - Ryan Allway

The achievement of an industry milestone providing access to psilocybin mushrooms to further their legal research as a treatment for mental health disorders TORONTO, May 19, 2021 /CNW/ – Wake Network, Inc. (“Wake,” or the “Company”), a global leader in psilocybin mushroom production and the developer of genomics-based integration therapies, is pleased to announce that […]

Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer

May 20th, 2021 - Ryan Allway

Dr. Raskin is a psychiatrist and academic with 20 years of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization   VANCOUVER, BC, May 20, 2021 /PRNewswire/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce the appointment of […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading